<h4>Objective</h4>To compare the real-world efficacy and safety of high dose once-weekly glucagon-like peptide-1 receptor agonists polyethylene glycol loxenatide (PEG-Loxe) and subcutaneous (s.c.)semaglutide in patients with suboptimally controlled type 2 diabetes mellitus (T2DM).<h4>Methods</h4>We conducted a retrospective cohort China two-center study. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.